ijms-logo

Journal Browser

Journal Browser

Neuromelanin, Peripheral Melanin and Parkinson's Disease

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Biochemistry".

Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 6754

Special Issue Editors


E-Mail Website
Guest Editor
Institute for Melanin Chemistry, Fujita Health University, Toyoake 470-1192, Aichi, Japan
Interests: UV damage; biosynthesis of melanin pathway; internal and external melanin; melanoma; fossil melanin; pro-oxidant activity
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Interests: neurodegenerative disorders; parkinson’s disease

Special Issue Information

Dear Colleagues,

Neuromelanin (NM), which appears as brown pigmented granules in the human central nervous system, is localized in brain regions such as the substantia nigra (SN) and the locus coeruleus (LC). Although it is reported that NM is structurally derived from DA and cysteinylDA, in contrast to DOPA for the cutaneous melanin, the biosynthesis and function of neuromelanin (NM) remain poorly understood. NM is known to accumulate in the human brain with aging. On the other hand, the degeneration of NM-containing dopaminergic neurons is a hallmark of Parkinson’s disease (PD), a common, age-related neurodegenerative disease. Additionally, PD has been consistently linked to melanoma, the deadliest skin cancer arising from melanin-producing melanocytes. For this Special Issue of IJMS, we are looking for research articles or reviews that can deliver profound insights into the mechanism of NM production with respect to PD, the role of NM in PD, the development of non-invasive methods for detecting NM as a biomarker for PD, and the potential for targeting the NM pathway as a therapeutic strategy for PD.

Prof. Dr. Kazumasa Wakamatsu
Dr. Xiqun Chen
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neuromelanin
  • Parkinson’s disease
  • substantia nigra
  • locus coeruleus
  • L-Dopamine
  • L-Norepinephrine
  • L-DOPA
  • melanoma

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

16 pages, 1968 KiB  
Review
Neuromelanin in Parkinson’s Disease: Tyrosine Hydroxylase and Tyrosinase
by Toshiharu Nagatsu, Akira Nakashima, Hirohisa Watanabe, Shosuke Ito and Kazumasa Wakamatsu
Int. J. Mol. Sci. 2022, 23(8), 4176; https://doi.org/10.3390/ijms23084176 - 10 Apr 2022
Cited by 41 | Viewed by 6145
Abstract
Parkinson’s disease (PD) is an aging-related disease and the second most common neurodegenerative disease after Alzheimer’s disease. The main symptoms of PD are movement disorders accompanied with deficiency of neurotransmitter dopamine (DA) in the striatum due to cell death of the nigrostriatal DA [...] Read more.
Parkinson’s disease (PD) is an aging-related disease and the second most common neurodegenerative disease after Alzheimer’s disease. The main symptoms of PD are movement disorders accompanied with deficiency of neurotransmitter dopamine (DA) in the striatum due to cell death of the nigrostriatal DA neurons. Two main histopathological hallmarks exist in PD: cytosolic inclusion bodies termed Lewy bodies that mainly consist of α-synuclein protein, the oligomers of which produced by misfolding are regarded to be neurotoxic, causing DA cell death; and black pigments termed neuromelanin (NM) that are contained in DA neurons and markedly decrease in PD. The synthesis of human NM is regarded to be similar to that of melanin in melanocytes; melanin synthesis in skin is via DOPAquinone (DQ) by tyrosinase, whereas NM synthesis in DA neurons is via DAquinone (DAQ) by tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AADC). DA in cytoplasm is highly reactive and is assumed to be oxidized spontaneously or by an unidentified tyrosinase to DAQ and then, synthesized to NM. Intracellular NM accumulation above a specific threshold has been reported to be associated with DA neuron death and PD phenotypes. This review reports recent progress in the biosynthesis and pathophysiology of NM in PD. Full article
(This article belongs to the Special Issue Neuromelanin, Peripheral Melanin and Parkinson's Disease)
Show Figures

Figure 1

Back to TopTop